Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Clinical trial NCT03810313 · TERMINATED
Trial details
- NCT number
- NCT03810313
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-03
- Primary completion
- 2021-07-26
- Enrollment
- 493
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.